AstraNova BioLabs helps biotech and pharmaceutical teams advance discovery programs with molecular pharmacology, assay development, screening, and integrated preclinical research expertise.
50+
Research Programs
20+
Assay Platforms
10+
Therapeutic Areas
AstraNova BioLabs was founded on the principle that the most transformative medicines emerge when scientific excellence meets operational discipline. We bring together world-class researchers, state-of-the-art platforms, and a deeply consultative approach to support every stage of your drug discovery journey.
From initial target validation through candidate selection and IND-enabling studies, our integrated team functions as a true extension of your organization — bringing transparency, urgency, and scientific insight to every milestone.
Every assay, every dataset, and every conclusion undergoes multi-layer validation to ensure reproducible, publication-quality results.
Deep familiarity with ICH guidelines and regulatory expectations ensures your preclinical data packages are built for IND success.
Optimized workflows and pre-validated platforms compress timelines by up to 40% compared to industry benchmarks.
From first-in-class target validation to IND-enabling candidate characterization, AstraNova's integrated capabilities support your program at every inflection point.
Full-spectrum modality profiling from small molecules and peptides through biologics and cell-gene therapies.
Sub-nanomolar precision in receptor binding kinetics, enzyme mechanism studies, and target engagement profiling.
High-content cellular screening in physiologically relevant 2D and 3D models including patient-derived organoids.
Custom assay design, rigorous validation, and miniaturization optimized for high-throughput screening campaigns.
Comprehensive target identification, validation, and mechanistic characterization across therapeutic modality classes.
AI-assisted drug design, cheminformatics, multi-omic data integration, and ADME prediction modeling.
Our integrated workflow is built to move your program efficiently through every stage of preclinical drug discovery — with scientific rigor at every decision point.
Systematic evaluation of disease-relevant molecular targets using genetic, biochemical, and computational approaches to confirm therapeutic rationale.
Key Deliverables
High-throughput and fragment-based screening campaigns against validated targets, deploying both biochemical and cell-based assay formats.
Key Deliverables
Iterative SAR profiling, ADME optimization, and selectivity assessment to advance hits through a rigorous multi-parameter optimization cascade.
Key Deliverables
Comprehensive mechanistic pharmacology, in vitro safety profiling, and translational biomarker development supporting candidate nomination decisions.
Key Deliverables
Coordination of preclinical data package assembly, regulatory-ready documentation, and scientific communication support for IND submission.
Key Deliverables
AstraNova maintains deep scientific expertise and purpose-built model systems across the therapeutic areas where novel medicines are needed most.
Comprehensive oncology programs spanning targeted therapies, immuno-oncology, and combination strategies. Our platforms encompass solid and hematological malignancies with patient-derived model systems for translational relevance.
Specialized CNS pharmacology platform with expertise in neuronal cell models, blood-brain barrier penetration studies, and mechanistic characterization of neurological disease targets.
Integrated cardiometabolic research capabilities including primary cardiac cell systems, metabolic flux analysis, and NASH/NAFLD translational models for cardiometabolic disease programs.
Advanced immune cell profiling, cytokine network analysis, and autoimmune disease modeling. Our platforms support the full spectrum of inflammatory targets from innate to adaptive immune mechanisms.
Antiviral, antibacterial, and antifungal drug discovery support with BSL-2 certified capabilities, resistance profiling, and host-directed therapy evaluation platforms.
Precision support for rare disease programs including patient-derived iPSC models, gene therapy vector characterization, and biomarker development for diseases with limited patient populations.
Purpose-built technology infrastructure enabling AstraNova to handle the most demanding drug discovery programs with speed, reproducibility, and regulatory readiness.
Our automated 1536-well screening infrastructure processes over 500,000 data points per campaign with integrated quality control, liquid handling precision monitoring, and real-time Z-factor analysis.
AstraNova's proprietary data management system integrates raw assay data, compound registry, dose-response modeling, and collaborative reporting into a single secure environment accessible to client teams.
Machine learning-assisted hit expansion, ADME prediction modeling, and structure-based design tools accelerate the chemical matter optimization cycle to generate smarter, more selective leads.
We don't measure ourselves against average — we measure ourselves against the standard your lead compound deserves.
Optimized workflows and pre-validated platforms compress timelines by up to 40% compared to industry benchmarks — without sacrificing scientific quality.
Every experiment is executed under strict QA oversight with full audit trails, raw data archiving, and ALCOA+ compliant documentation practices.
Your program receives a named team — not a rotating pool — ensuring deep program knowledge, continuity, and genuine scientific ownership.
Real-time access to data, progress dashboards, and milestone reporting ensures you are never in the dark during critical program phases.
From biochemical primary screening through phenotypic confirmation and translational characterization, we provide continuity across the discovery cascade.
Strategic partnerships with leading academic centers, genomics providers, and specialty labs extend our capabilities to address even the most complex scientific questions.
AstraNova BioLabs announces the expansion of its phenotypic oncology platform with a validated library of 48 patient-derived tumor organoid lines representing 12 cancer indications, enabling translational research with unprecedented relevance to clinical biology.
Read MoreResearchers from AstraNova's molecular pharmacology group and collaborating academic partners publish a validated platform for high-throughput PROTAC degradation kinetics and ternary complex assessment in Nature Chemical Biology.
Read MoreSignificant expansion of AstraNova's neuroscience capabilities with the addition of isogenic iPSC-derived neuronal models from patients carrying disease-relevant genetic variants, enabling mechanism-matched efficacy assessment.
Read MoreBring us the program question, constraints, and next decision point. We will map the right assays, controls, timeline, and reporting package before the first plate is run.
